Investors
News
Subscribe
Hit enter to search or ESC to close
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Cardiovascular Disease
Metabolic Disease
Liver Disease
Arthritis
Aging
Coronavirus Disease 2019 (COVID-19)
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact Us
Financial Results
Investor Relations
Investors
Overview
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
Company Info
Profile
Management Team
Contacts
FAQ
Financial Info
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
2021
Q1 2021
Quarter Ended Mar 31, 2021
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2020
FY 2020
Fiscal Year Ended Dec 31, 2020
PDF
HTML
Release
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2020
Quarter Ended Sep 30, 2020
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2020
Quarter Ended Jun 30, 2020
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2020
Quarter Ended Mar 31, 2020
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2019
FY 2019
Fiscal Year Ended Dec 31, 2019
PDF
HTML
Release
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2019
Quarter Ended Sep 30, 2019
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2019
Quarter Ended Jun 30, 2019
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2019
Quarter Ended Mar 31, 2019
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2018
FY 2018
Fiscal Year Ended Dec 31, 2018
PDF
HTML
Release
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2018
Quarter Ended Sep 30, 2018
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2018
Quarter Ended Jun 30, 2018
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2018
Quarter Ended Mar 31, 2018
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2017
FY 2017
Fiscal Year Ended Dec 31, 2017
PDF
HTML
Release
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2017
Quarter Ended Sep 30, 2017
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2017
Quarter Ended Jun 30, 2017
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2017
Quarter Ended Mar 31, 2017
PDF
HTML
Release
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2016
FY 2016
Fiscal Year Ended Dec 31, 2016
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2016
Quarter Ended Sep 30, 2016
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2016
Quarter Ended Jun 30, 2016
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2016
Quarter Ended Mar 31, 2016
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2015
FY 2015
Fiscal Year Ended Dec 31, 2015
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2015
Quarter Ended Sep 30, 2015
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2015
Quarter Ended Jun 30, 2015
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2015
Quarter Ended Mar 31, 2015
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2014
FY 2014
Fiscal Year Ended Dec 31, 2014
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2014
Quarter Ended Sep 30, 2014
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2014
Quarter Ended Jun 30, 2014
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2014
Quarter Ended Mar 31, 2014
PDF
HTML
10-Q
Filing
PDF
HTML
10-Q/A
Filing
ZIP
XLS
HTML
XBRL
2013
FY 2013
Fiscal Year Ended Dec 31, 2013
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Financial Information
Balance Sheet
Income Statement
Cash Flow
Financial Results
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Investor Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Contact Us
Investors
News
Subscribe